RETA -8% on phase-1b data for Omaveloxolone/Opdivo in melanoma: https://globenewswire.com/news-release/2017/12/11/1250708/0/en/Reata-Pharmaceuticals-Inc-Presents-Interim-Phase-1b-Data-for-Omaveloxolone-in-the-Treatment-of-Unresectable-or-Metastatic-Melanoma.html